Contact HealthDay
Tel: 203.855.1400 or E-mail

News By Specialty

Allergy
Anesthesiology
Cardiology
Cosmetic Surgery
Critical Care
Dermatology
Diabetes & Endocrinology
Emergency Medicine
Family Practice
Gastroenterology
Geriatrics
Hematology & Oncology
HIV & AIDS
Infectious Disease
Internal Medicine
Nephrology
Neurology
Nursing
OBGYN & Women's Health
Ophthalmology
Orthopedics
Otolaryngology
Pain Management
Pathology
Pediatrics
Pharmacy
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology

Follow us on:

    


e-Healthcare Leadership Awards


Stimulant Still Available for Sale Despite FDA Action
DMAA marketed as a dietary supplement

WEDNESDAY, Dec. 5 (HealthDay News) -- Products containing 1,3-dimethylamylamine (DMAA), a stimulant marketed as a dietary supplement in the United States, are still available for sale despite a warning from the U.S. Food and Drug Administration, according to a research letter published online Dec. 3 in the Archives of Internal Medicine.

Philip J. Gregory, Pharm.D., from Creighton University in Omaha, Neb., surveyed whether 16 products containing DMAA were available for sale through online retailers as of May 17, 2012. The FDA had sent warning letters to the manufacturers of these products on April 27, 2012, stating that the products were considered adulterated because DMAA is considered a new dietary ingredient. A manufacturer of a new dietary ingredient is required to submit documentation demonstrating the expectation of safety; if this documentation is not received, the FDA considers the product to be an unapproved drug.

Gregory found that all 16 products were still available for sale, either through online retailers or directly from the manufacturer. None of the Web sites noted that the products were illegal, adulterated, and generally not permitted for sale.

"Despite this warning, all of the products in question are still readily available," Gregory concludes. "This suggests that the FDA's warning process may do little to nothing to stem the significant public health risk posed by this potentially dangerous ingredient."

Full Text (subscription or payment may be required)



Copyright © 2012 HealthDay. All rights reserved.

June 18, 2013

Archive Search

By Keyword:
By Category:
By Topic:

Related Articles

Some Antibiotics Up Risk of Statin Toxicity in Older Adults

FDA Discusses Cybersecurity for Medical Devices, Hospitals

Local Health Departments Beginning to Use Twitter

ENDO: INSL33 Levels Decreased in Cryptorchidism

Only a Quarter of New Doctors Choose Primary Care

Duloxetine Moderately Cost-Effective for Treating Back Pain